Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conferen...
February 15 2018 - 4:05PM
Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it
will report its 2017 financial results and provide a corporate
update on
February 22, 2018. The Company will also
host a conference call that day at 5:00 p.m. Eastern Time (2:00
p.m. Pacific Time).
Conference Call Information
To participate, dial 1-800-289-0459 from the
United States or 1-323-794-2558 internationally approximately 10
minutes before the start of the call. The passcode is 094798.
A replay will be available through March 8, 2018 at
1-888-203-1112 from the United States and 1-719-457-0820
internationally. The passcode will be 1581123.
About Corcept
Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in
the discovery, development and commercialization of drugs that
treat severe metabolic, oncologic and psychiatric disorders by
modulating the effects of cortisol. Korlym is the company’s
first FDA-approved medication. Corcept has a large portfolio of
proprietary compounds that selectively modulate the effects of
cortisol but not progesterone. Corcept owns extensive United States
and foreign intellectual property covering the use of cortisol
modulators in the treatment of a wide variety of serious disorders,
including Cushing’s syndrome. It also holds composition of matter
patents covering its selective cortisol modulators.
CONTACT:Charles RobbChief Financial
OfficerCorcept
Therapeutics650-688-8783crobb@corcept.comwww.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Sep 2023 to Sep 2024